Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARDT NASDAQ:AVAH NASDAQ:VMD NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health$10.00+0.5%$9.28$8.07▼$15.48$1.43B0.93394,673 shs25,055 shsAVAHAveanna Healthcare$6.73+2.0%$6.73$3.73▼$10.32$1.47B1.931.20 million shs238,357 shsVMDViemed Healthcare$9.12+1.0%$9.37$5.93▼$10.18$350.78M1.15251,987 shs33,419 shsVRDNViridian Therapeutics$16.86-2.0%$21.08$12.07▼$34.29$1.74B0.822.32 million shs367,133 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health-1.55%-1.59%+6.15%+11.06%-31.13%AVAHAveanna Healthcare-2.23%-0.30%+5.95%-16.16%+21.59%VMDViemed Healthcare+1.01%-9.43%-5.05%+8.93%+42.88%VRDNViridian Therapeutics+3.55%+28.17%+15.05%-42.78%+37.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDTArdent Health$10.00+0.5%$9.28$8.07▼$15.48$1.43B0.93394,673 shs25,055 shsAVAHAveanna Healthcare$6.73+2.0%$6.73$3.73▼$10.32$1.47B1.931.20 million shs238,357 shsVMDViemed Healthcare$9.12+1.0%$9.37$5.93▼$10.18$350.78M1.15251,987 shs33,419 shsVRDNViridian Therapeutics$16.86-2.0%$21.08$12.07▼$34.29$1.74B0.822.32 million shs367,133 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDTArdent Health-1.55%-1.59%+6.15%+11.06%-31.13%AVAHAveanna Healthcare-2.23%-0.30%+5.95%-16.16%+21.59%VMDViemed Healthcare+1.01%-9.43%-5.05%+8.93%+42.88%VRDNViridian Therapeutics+3.55%+28.17%+15.05%-42.78%+37.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDTArdent Health 2.36Hold$14.2142.15% UpsideAVAHAveanna Healthcare 2.55Moderate Buy$10.2552.42% UpsideVMDViemed Healthcare 2.00HoldN/AN/AVRDNViridian Therapeutics 2.79Moderate Buy$37.31121.33% UpsideCurrent Analyst Ratings BreakdownLatest VMD, VRDN, AVAH, and ARDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026ARDTArdent Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $13.505/6/2026VRDNViridian Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $34.005/5/2026VRDNViridian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.004/21/2026VRDNViridian Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.004/20/2026VRDNViridian Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026AVAHAveanna Healthcare Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$9.00 ➝ $8.004/8/2026VRDNViridian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$37.00 ➝ $31.004/7/2026VRDNViridian Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $31.004/7/2026VRDNViridian Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $30.004/6/2026AVAHAveanna Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)3/31/2026VRDNViridian Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $36.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDTArdent Health$6.32B0.23$2.72 per share3.68$11.78 per share0.85AVAHAveanna Healthcare$2.43B0.60$0.69 per share9.77$0.93 per share7.23VMDViemed Healthcare$286.57M1.22$1.17 per share7.76$3.78 per share2.41VRDNViridian Therapeutics$70.92M24.50N/AN/A$6.18 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDTArdent Health$135.81M$0.9510.498.262.252.09%13.85%4.48%N/AAVAHAveanna Healthcare$225.03M$1.026.6110.51N/A9.25%481.69%6.08%5/14/2026 (Estimated)VMDViemed Healthcare$14.93M$0.3724.7315.19N/A5.20%10.52%7.60%N/AVRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%N/ALatest VMD, VRDN, AVAH, and ARDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026AVAHAveanna Healthcare$0.13N/AN/AN/A$613.22 millionN/A5/5/2026Q1 2026ARDTArdent Health$0.18$0.28+$0.10$0.28$1.58 billion$1.60 billion5/5/2026Q1 2026VMDViemed Healthcare$0.09$0.06-$0.03$0.06$74.40 million$75.41 million5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 million3/4/2026Q4 2025ARDTArdent Health$0.35$0.32-$0.03$0.32$1.63 billion$1.61 billion3/4/2026Q4 2025VMDViemed Healthcare$0.12$0.14+$0.02$0.14$77.70 million$76.18 million2/26/2026Q4 2025VRDNViridian Therapeutics-$0.90-$1.08-$0.18-$1.08$15.75 million$0.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDTArdent HealthN/AN/AN/AN/AN/AAVAHAveanna HealthcareN/AN/AN/AN/AN/AVMDViemed HealthcareN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDTArdent Health0.622.122.00AVAHAveanna Healthcare6.621.321.32VMDViemed Healthcare0.061.221.10VRDNViridian Therapeutics0.1015.1515.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDTArdent HealthN/AAVAHAveanna Healthcare87.96%VMDViemed Healthcare74.24%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARDTArdent Health1.90%AVAHAveanna Healthcare5.30%VMDViemed Healthcare20.00%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDTArdent Health25,200143.35 million140.63 millionOptionableAVAHAveanna Healthcare35,500217.51 million205.98 millionOptionableVMDViemed Healthcare1,38238.34 million30.67 millionNot OptionableVRDNViridian Therapeutics50103.08 million100.60 millionOptionableVMD, VRDN, AVAH, and ARDT HeadlinesRecent News About These CompaniesVanguard Group Inc. Raises Holdings in Viridian Therapeutics, Inc. $VRDNMay 11 at 7:09 AM | marketbeat.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - SlideshowMay 9 at 8:05 PM | seekingalpha.comViridian Therapeutics (NASDAQ:VRDN) Upgraded at Wall Street ZenMay 9 at 1:34 AM | marketbeat.comEarnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their EstimatesMay 8, 2026 | finance.yahoo.comWhy Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh FundraisingMay 8, 2026 | finance.yahoo.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comViridian Therapeutics' (VRDN) "Buy" Rating Reiterated at Needham & Company LLCMay 8, 2026 | americanbankingnews.comBrokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $37.07May 8, 2026 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Sees Large Volume Increase - Time to Buy?May 7, 2026 | marketbeat.comViridian (VRDN) Climbs 33% on Looming Drug CommercializationMay 7, 2026 | finance.yahoo.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350 ...May 7, 2026 | finance.yahoo.comViridian Therapeutics prices upsized $350M concurrent stock and convertible notes offeringsMay 7, 2026 | msn.comViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionMay 6, 2026 | businesswire.comViridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLCMay 6, 2026 | marketbeat.comPrivium Fund Management B.V. Acquires Shares of 173,516 Viridian Therapeutics, Inc. $VRDNMay 6, 2026 | marketbeat.comViridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TEDMay 6, 2026 | marketbeat.comViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseMay 5, 2026 | timesargus.comTPDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 ResultsMay 5, 2026 | finance.yahoo.comViridian eye disease drug surpasses expectations in late-stage trial; shares soarMay 5, 2026 | msn.comVRDN stock records biggest single day gains in 45 months – and it’s not just due to a better-than-feared Q1 lossMay 5, 2026 | msn.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptMay 5, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVMD, VRDN, AVAH, and ARDT Company DescriptionsArdent Health NYSE:ARDT$9.99 +0.05 (+0.45%) As of 11:17 AM Eastern This is a fair market value price provided by Massive. Learn more.Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.Aveanna Healthcare NASDAQ:AVAH$6.72 +0.14 (+2.05%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.Viemed Healthcare NASDAQ:VMD$9.12 +0.09 (+0.95%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.Viridian Therapeutics NASDAQ:VRDN$16.86 -0.34 (-2.00%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
